Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations
The Oncologist · 10.04.2026 · 31 (5)
DOI: 10.1093/oncolo/oyag143 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Oncologist, online erschienen am 16.04.2026. Verfasst von Elena Castro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, i+12 Biomedical Research Institute.Hospital Universitario 12 de Octubre, Madrid, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Background
Without head-to-head trials comparing talazoparib plus enzalutamide (TALA+ENZA), olaparib plus abiraterone acetate and prednisone (OLAP+AAP), and niraparib plus abiraterone acetate and prednisone (NIRA+AAP) as first-line treatments for metastatic castration-resistant prostate cancer (mCRPC), treatment selection remains challenging. This study estimated the relative efficacy of TALA+ENZA vs OLAP+AAP and NIRA+AAP in unselected, homologous recombination repair (HRR)-deficient, and BRCA-mutated (BRCAm) populations.
Methods
Unanchored matching-adjusted indirect comparisons (MAICs) were conducted using individual patient data from TALAPRO-2 (TALA+ENZA) and published summary-level data from PROpel (OLAP+AAP) and MAGNITUDE (NIRA+AAP). TALAPRO-2 patients meeting PROpel/MAGNITUDE eligibility criteria were included; remaining patients were reweighted to align on key baseline characteristics. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for radiographic progression-free survival (rPFS) and overall survival (OS).
Results
In unselected patients, TALA+ENZA significantly prolonged rPFS vs OLAP+AAP (HR: 0.747; 95% CI, 0.583, 0.957), with no OS difference (HR: 0.821; 95% CI, 0.649, 1.039). In HRR-deficient patients, TALA+ENZA significantly prolonged rPFS vs OLAP+AAP (HR: 0.648; 95% CI, 0.423, 0.992), with no OS difference (HR: 0.834; 95% CI, 0.569, 1.223). Comparisons with OLAP+AAP in BRCAm were infeasible. Compared with NIRA+AAP, TALA+ENZA significantly prolonged rPFS and OS in HRR-deficient (HR: 0.406; 95% CI, 0.251, 0.655; HR: 0.554; 95% CI, 0.340, 0.902) and BRCAm patients (HR: 0.394; 95% CI, 0.222, 0.698; HR: 0.472; 95% CI, 0.247, 0.902).
Conclusions
MAICs showed improved clinical benefit with TALA+ENZA vs OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, i+12 Biomedical Research Institute.Hospital Universitario 12 de Octubre, Madrid, Spain.
- EVERSANA™, Burlington, Ontario, L7N 3H8, Canada.
- EVERSANA™, New York, NY, 10018, United States.
- Pfizer, Inc., New York, NY, 10001, United States.
ORCID-Profile: Imtiaz A Samjoo
Förderung
- Pfizer Inc
Zitieren
APA
Castro, E., Wang, D., Paganelli, S., Haltner, A., Su, N., Kirker, M., Chang, J., & Samjoo, I. A. (2026). Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag143
Vancouver
Castro E, Wang D, Paganelli S, Haltner A, Su N, Kirker M, et al. Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag143
BibTeX
@article{Castro2026,
author = {Castro, Elena and Wang, Di and Paganelli, Stefanie and Haltner, Anja and Su, Neo and Kirker, Melissa and Chang, Jane and Samjoo, Imtiaz A},
title = {Matching-adjusted indirect comparisons of PARP inhibitor combinations in metastatic castration-resistant prostate cancer across key populations},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {5},
doi = {10.1093/oncolo/oyag143}
}
EUVIMED